Key facts: Deramiocel Hits HOPE-3 Endpoint; Heart Data NS, FDA Odds 62%
Capricor Therapeutics (CAPR) reported that deramiocel met the primary endpoint in its Phase 3 HOPE-3 trial, improving upper-limb function. However, overall heart function results were not statistically significant. BiopharmaWatch estimated a 62% chance of FDA approval for Deramiocel, with a decision expected soon.
How this was made

The 30-second read
Why it matters
The primary‑endpoint success is a key catalyst for valuation, moving the probability of FDA approval from speculative to quantifiable.
Market read
First‑time disclosure of pivotal trial data provides a fresh trading signal for CAPR and may influence peer biotech valuations.
What to watch
Regulatory timing and potential competition from other therapies are not addressed in the article.
Background
Capricor Therapeutics (NASDAQ:CAPR) is a small‑cap biotech focused on gene‑editing therapies for rare cardiac and muscular diseases.
Ticker impact
Capricor Therapeutics reported that its drug deramiocel met the primary endpoint in the Phase 3 HOPE-3 trial, a first‑time disclosure of pivotal data.
likely upward pressure as the market prices in the 62% FDA approval probability.
Trial success is material for a biotech; the article is the first report of the data, making the information novel and actionable.
Market effects
Other gene‑therapy and rare‑disease biotech stocks may see increased interest as the trial success raises sector optimism.
US biotech sector could benefit from the news, with modest spill‑over to Nasdaq biotech indices.
International investors tracking FDA pipelines may adjust exposure to similar companies.
Counterpoint
The 38% chance that the trial fails to meet secondary endpoints or safety concerns could limit upside.
Key entities
- companyCapricor Therapeutics
Biotech developer of deramiocel.

